10 October 2024 - The MHRA has today approved an adapted Pfizer/BioNTech COVID-19 vaccine (Comirnaty) that targets the KP.2 COVID-19 sub-variant for adults.

Two presentations of this adapted Comirnaty KP.2 COVID-19 vaccine have been approved by the MHRA under the International Recognition Procedure after they were found to meet the UK regulator’s standards of safety, quality, and effectiveness.

Read UK Government press release